D. WESTERN THERAPEUTICS INSTITUTE, INC. Financials D. Western Therapeutics Institute, Inc.
Equities
4576
JP3548740004
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 109 JPY | +3.81% |
|
+0.93% | -22.70% |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 15,082 | 17,053 | 8,454 | 6,341 | 7,998 | 4,530 |
| Enterprise Value (EV) 1 | 14,098 | 15,993 | 6,606 | 4,747 | 6,631 | 3,547 |
| P/E ratio | -20.2 x | 128 x | -28.5 x | -42.8 x | -18.1 x | -5.52 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 51.7 x | 29.4 x | 23.8 x | 15.3 x | 17.9 x | 10.6 x |
| EV / Revenue | 48.3 x | 27.6 x | 18.6 x | 11.5 x | 14.8 x | 8.29 x |
| EV / EBITDA | -19.2 x | 99.3 x | -29.8 x | -37.4 x | -25.5 x | -4.73 x |
| EV / FCF | -54.3 x | 400 x | -50.9 x | -37.7 x | -29.5 x | -11.2 x |
| FCF Yield | -1.84% | 0.25% | -1.96% | -2.65% | -3.39% | -8.94% |
| Price to Book | 12 x | 12.2 x | 3.91 x | 3.16 x | 4.36 x | 3.54 x |
| Nbr of stocks (in thousands) | 26,275 | 26,275 | 29,251 | 29,359 | 30,527 | 32,128 |
| Reference price 2 | 574.0 | 649.0 | 289.0 | 216.0 | 262.0 | 141.0 |
| Announcement Date | 28/03/19 | 26/03/20 | 23/03/21 | 29/03/22 | 30/03/23 | 27/03/24 |
1JPY in Million2JPY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 292 | 580 | 355 | 414 | 448 | 428 |
| EBITDA 1 | -736 | 161 | -222 | -127 | -260 | -750 |
| EBIT 1 | -787 | 117 | -266 | -172 | -306 | -798 |
| Operating Margin | -269.52% | 20.17% | -74.93% | -41.55% | -68.3% | -186.45% |
| Earnings before Tax (EBT) 1 | -801 | 109 | -290 | -159 | -440 | -826 |
| Net income 1 | -748 | 133 | -276 | -148 | -429 | -812 |
| Net margin | -256.16% | 22.93% | -77.75% | -35.75% | -95.76% | -189.72% |
| EPS 2 | -28.47 | 5.062 | -10.16 | -5.045 | -14.47 | -25.55 |
| Free Cash Flow 1 | -259.6 | 40 | -129.8 | -126 | -225.1 | -317 |
| FCF margin | -88.91% | 6.9% | -36.55% | -30.43% | -50.25% | -74.07% |
| FCF Conversion (EBITDA) | - | 24.84% | - | - | - | - |
| FCF Conversion (Net income) | - | 30.08% | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 28/03/19 | 26/03/20 | 23/03/21 | 29/03/22 | 30/03/23 | 27/03/24 |
1JPY in Million2JPY
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: |
|---|
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | 984 | 1,060 | 1,848 | 1,594 | 1,367 | 983 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | -260 | 40 | -130 | -126 | -225 | -317 |
| ROE (net income / shareholders' equity) | -47.3% | 7.98% | -16.3% | -7.62% | -22.6% | -52.5% |
| ROA (Net income/ Total Assets) | -19.9% | 3.61% | -7.05% | -4.14% | -7.06% | -18.7% |
| Assets 1 | 3,764 | 3,687 | 3,916 | 3,579 | 6,077 | 4,338 |
| Book Value Per Share 2 | 47.90 | 53.00 | 73.90 | 68.30 | 60.10 | 39.80 |
| Cash Flow per Share 2 | 60.30 | 58.60 | 78.90 | 65.80 | 75.60 | 58.10 |
| Capex 1 | 6 | - | 5 | 2 | 9 | 12 |
| Capex / Sales | 2.05% | - | 1.41% | 0.48% | 2.01% | 2.8% |
| Announcement Date | 28/03/19 | 26/03/20 | 23/03/21 | 29/03/22 | 30/03/23 | 27/03/24 |
1JPY in Million2JPY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -22.70% | 21.74M | |
| +3.91% | 109B | |
| +10.87% | 105B | |
| +0.09% | 22.25B | |
| -13.14% | 22.09B | |
| -7.80% | 18.68B | |
| -38.36% | 17.58B | |
| -10.66% | 16.85B | |
| +3.75% | 13.76B | |
| +36.70% | 12.46B |
- Stock Market
- Equities
- 4576 Stock
- Financials D. Western Therapeutics Institute, Inc.
